Author:
Eberle Franziska C.,Brück Jürgen,Holstein Julia,Hirahara Kiyoshi,Ghoreschi Kamran
Abstract
T helper (Th) cells producing interleukin (IL)-17, IL-22, and tumor necrosis factor (TNF) form the key T cell population driving psoriasis pathogenesis. They orchestrate the inflammation in the skin that results in the proliferation of keratinocytes and endothelial cells. Besides Th17 cells, other immune cells that are capable of producing IL-17-associated cytokines participate in psoriatic inflammation. Recent advances in psoriasis research improved our understanding of the cellular and molecular players that are involved in Th17 pathology and inflammatory pathways in the skin. The inflammation-driving actions of TNF in psoriasis are already well known and antibodies against TNF are successful in the treatment of Th17-mediated psoriatic skin inflammation. A further key cytokine with potent IL-17-/IL-22-promoting properties is IL-23. Therapeutics directly neutralizing IL-23 or IL-17 itself are now extending the therapeutic spectrum of antipsoriatic agents and further developments are on the way. The enormous progress in psoriasis research allows us to control this Th17-mediated inflammatory skin disease in many patients.
Subject
General Pharmacology, Toxicology and Pharmaceutics,General Immunology and Microbiology,General Biochemistry, Genetics and Molecular Biology,General Medicine
Reference74 articles.
1. Advances in treating psoriasis.;K Belge;F1000Prime Rep.,2014
2. Psoriasis.;F Nestle;N Engl J Med.,2009
3. Immunology of psoriasis.;M Lowes;Annu Rev Immunol.,2014
4. Psoriasis.;W Boehncke;Lancet.,2015
5. Angiogenesis drives psoriasis pathogenesis.;R Heidenreich;Int J Exp Pathol.,2009
Cited by
103 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献